DMG MORI AKTIENGESELLSCHAFT

  • WKN: 587800
  • ISIN: DE0005878003
  • Land: Deutschland

Nachricht vom 09.02.2021 | 16:27

DMG MORI AKTIENGESELLSCHAFT: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]

DMG MORI AKTIENGESELLSCHAFT / Preliminary announcement on the disclosure of financial statements
09.02.2021 / 16:27
Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DMG MORI AKTIENGESELLSCHAFT hereby announces that the following financial reports shall be disclosed:

Report Type: Annual financial report

Language: German
Date of disclosure: March 09, 2021
Address: http://dmgmori.com/ag-gb-2020

Language: English
Date of disclosure: March 09, 2021
Address: http://dmgmori.com/ag-ar-2020

Report Type: Annual financial report of the group

Language: German
Date of disclosure: March 09, 2021
Address: http://dmgmori.com/ag-gb-2020-jl

Language: English
Date of disclosure: March 09, 2021
Address: http://dmgmori.com/ag-ar-2020-fs

Report Type: Financial report of the group (half-year/Q2)

Language: German
Date of disclosure: July 23, 2021
Address: http://dmgmori.com/ag-zb-2021-02

Language: English
Date of disclosure: July 23, 2021
Address: https://dmgmori.com/ag-ir-2021-02


09.02.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Infineon Technologies AG: Aufsichtsrat beruft Jochen Hanebeck zum Nachfolger von Dr. Reinhard Ploss als Vorstandsvorsitzenden von Infineon

25. November 2021, 17:45

Aktuelle Research-Studie

3U HOLDING AG

Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021